writeoutloud.net /1 week ago

occhiole

 ...

Read source
deccanchronicle.com /1 month ago

Odisha's KIMS Performs First Corneal Transplant, Restores Vision Of 37-Year-Old

The surgery was performed by a team of ophthalmologists led by Dr Akshit Gupta.

Read source
medcitynews.com /4 weeks ago

Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...

Read source
medcitynews.com /5 days ago

J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding

Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offers advantages over Vabysmo, a Roche drug a...

Read source
opticaljournal.com /1 month ago

Orthokeratologist.org Launches To Unite Orthokeratologists Around The World

Orthokeratologist.org, the world’s first dedicated community for orthokeratologists, has launched today with a global call out to all orthokeratologists to step forward and be coun...

Read source
seekingalpha.com /1 month ago

Alcon wins approval of OTC Brytly eye drops

Read source
medinform.jmir.org /3 weeks ago

Secure Patient Messaging in Ophthalmology: Retrospective Natural Language Processing Study

Background: The rapid rise of secure patient messaging has transformed ophthalmic communication, with text volumes now exceeding prepandemic levels across health care systems. Our...

Read source
investmentwatchblog.com /1 month ago

ER-100 – aging reversal drug first test results in the EYE with Glaucoma announced

Safety phase. 2 of 3 patients given LOW DOSES reported vision improvement. Phase 2 – Doses will now triple in size for next round. Today, at the American Academy of Ophthalmology A...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.